Specialist Updates 
Oncology

Postoperative radiotherapy ‘not advisable’ in advanced NSCLC

Trial findings clarify lack of benefit and increased cardiopulmonary toxicity
Medicom Staff writer
0
24 September 2020
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

Postoperative radiotherapy cannot be routinely recommended for patients with completely resected stage III N2 non-small cell lung cancer, researchers say after conducting a randomised controlled trial.

The keenly-awaited results follow a long-running controversy over use of postoperative radiotherapy (PORT) since a 1998 Lancet meta-analysis cast doubt on benefit and showed adverse effects in lower risk patients (stage I to II NO or N1 cancers).

At the European Society for Medical Oncology (ESMO) virtual congress 2020 this week, researchers presented the results of the LungART trial of 500 patients with stage III N2 non-small cell lung cancer (NSCLC).

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .